ArticleNeuro-oncology2025
AI differentiates radionecrosis from true progression in brain metastasis upon stereotactic radiosurgery: Analysis of 124 histologically assessed lesions.
Article in Neuro-oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Radiomics using contrast-enhanced T1-weighted imaging and clinical features for predicting response to EGFR-TKIs in EGFR-mutated non-small cell lung cancer patients with brain metastases.BMC medical imaging · 2026Article
- Predicting Recurrence Risk of Glioblastoma Based on Preoperative-Postoperative Longitudinal MRI: A Multicenter Study.Bioengineering (Basel, Switzerland) · 2026Article
- Radionecrosis risk and local control after CyberKnifeRadiation oncology (London, England) · 2026Article
- RN-DFrontiers in artificial intelligence · 2026Article
- Multicenter development of a deep learning radiomics and dosiomics nomogram to predict radiation pneumonia risk in non-small cell lung cancer.Scientific reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
Abstract
backgroundDifferentiating radionecrosis from neoplastic progression after stereotactic radiosurgery (SRS) for brain metastases is a diagnostic challenge. Previous studies have often been limited by datasets lacking histologically confirmed diagnoses. This study aimed to develop automated models for distinguishing radionecrosis from disease progression on brain MRI, utilizing cases with definitive histopathological confirmation.
methodsThis multi-center retrospective study included patients who underwent surgical resection for suspected brain metastasis progression after SRS. Presurgical FLAIR and postcontrast T1 (T1w-ce) were segmented using a convolutional neural network (CNN) and compared with manual segmentation by means of Dice score. Radiomics features were extracted from each lesion, and a Random Forest model was trained on 70% of the internal dataset and evaluated on the remaining 30% and the complete external dataset. A 3DResNet-CNN was trained on the same split dataset. Validation was performed on the external dataset. Postsurgical histology was available for all cases.
resultsOne hundred and twenty four brain metastases were included (104 from center 1 and 20 from center 2). Sole radionecrosis was histologically detected in 34 cases (27.4%). In the internal dataset, univariate and multivariate analysis identified 131 significantly different radiomics features, including GLDM_DNUN and GLDM_SDE within the enhancing area on the T1w-ce. On the external test dataset, the Random Forest model and the 3DResNet-CNN yielded accurate results in terms of accuracy (80.0%, 85.0%), AUROC (0.830, 0.893) and sensitivity (92.8%, 100%) in radionecrosis prediction, respectively.
conclusionArtificial intelligence could be employed to differentiate between radionecrosis and brain metastasis progression upon SRS, potentially reducing unnecessary surgical interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.